By Dhirendra Tripathi
Investing.com – Novavax (NASDAQ: NVAX ) extended losses for the second consecutive day, plunging 12% in Tuesday’s trade a day after the vaccine maker said it is pushing back its timetable for seeking regulatory approvals for its Covid-19 shot.
The company said it intended to apply for permissions in the U.S, the U.K. and Europe in the next quarter.
Cumulatively, Novavax share price is now down by more than half of its year’s high of $331.
Market makers are puzzled by the continuing delay at the company’s end at a time when the likes of Pfizer (NYSE: PFE )-BioNTech (NASDAQ: BNTX ) and Moderna (NASDAQ: MRNA ) have supplied millions of doses in the U.S., and AstraZeneca (NASDAQ: AZN ) has done so in Europe and India.
A Washington Post report Monday said the company delayed plans to seek emergency use authorization.
The Gaithersburg-based vaccine developer is yet to supply a single dose even as it has manufacturing agreements with India’s Serum Institute, Japan’s Takeda and South Korea’s SK Bioscience to make the shots.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.